About P2Y purinoceptor 1
P2Y purinoceptor 1 (P2RY1) is a protein
from Homo sapiens identified by UniProt accession
P47900, 373 residues long.
MolForge cross-references it against 0 known binders and
259 disease associations.
Target properties
| Protein name | P2Y purinoceptor 1 |
|---|
| UniProt accession | P47900 |
|---|
| Gene | P2RY1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 373 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (259)
Diseases linked to this target (Open Targets).
- dry eye syndrome · score 0.55
- type 2 diabetes mellitus · score 0.42
- HbA1c measurement · score 0.36
- glucose measurement · score 0.29
- chronotype measurement · score 0.28
- mathematical ability · score 0.27
- hemoglobin A1 measurement · score 0.26
- breast adenocarcinoma · score 0.25
- body weight · score 0.13
- cutaneous melanoma · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P47900-F1 | alphafold | PREDICTED | 85.31 | — |
Amino-acid sequence (373 residues)
MTEVLWPAVP NGTDAAFLAG PGSSWGNSTV ASTAAVSSSF KCALTKTGFQ FYYLPAVYIL VFIIGFLGNS VAIWMFVFHM KPWSGISVYM FNLALADFLY VLTLPALIFY YFNKTDWIFG DAMCKLQRFI FHVNLYGSIL FLTCISAHRY SGVVYPLKSL GRLKKKNAIC ISVLVWLIVV VAISPILFYS GTGVRKNKTI TCYDTTSDEY LRSYFIYSMC TTVAMFCVPL VLILGCYGLI VRALIYKDLD NSPLRRKSIY LVIIVLTVFA VSYIPFHVMK TMNLRARLDF QTPAMCAFND RVYATYQVTR GLASLNSCVD PILYFLAGDT FRRRLSRATR KASRRSEANL QSKSEDMTLN ILPEFKQNGD TSL
Explore P2Y purinoceptor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets